Q-omics provides the consensus-scored PON3 profile across patient tissues and cancer cell-line models. PON3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PON3 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, PON3 protein abundance shows 16,422 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, KIRP, and LSCC as cancer lineages where PON3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PON3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PON3 survival associations across molecular data types. PON3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PON3 RNA expression–survival associations across cancer types. High PON3 expression shows unfavorable associations in UCS, KIRP, ACC, COAD and UCEC, but favorable associations in LGG. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PON3 RNA expression.
This table summarizes PON3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PON3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PON3 shows lower tumor expression in KIRP, KICH, KIRC, LUSC, UCEC and LIHC. The KIRP box plot shows higher PON3 RNA expression in normal versus tumor tissue (log2 FC = −1.695, t-test p < 0.001).
This table shows molecular features associated with PON3 in patient tissues and cancer cell lines. In patient samples, PON3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PON3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
